Statera BioPharma (STU:7CB) FCF Margin %: 0.00% (As of Sep. 2022)


What is Statera BioPharma FCF Margin %?

Statera BioPharma STU:7CB 20 FCF Margin % is 0.00% as of Sep. 2022. GuruFocus rates STU:7CB with a GF Score™ of 20/100. The stock has 1 warning sign investors should review.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Statera BioPharma's Free Cash Flow for the three months ended in Sep. 2022 was €-0.81 Mil. Statera BioPharma's Revenue for the three months ended in Sep. 2022 was €0.00 Mil. Therefore, Statera BioPharma's FCF Margin % for the quarter that ended in Sep. 2022 was 0.00%.

As of today, Statera BioPharma's current FCF Yield % is -10.03%.

The historical rank and industry rank for Statera BioPharma's FCF Margin % or its related term are showing as below:


STU:7CB's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -85.21
* Ranked among companies with meaningful FCF Margin % only.

Statera BioPharma FCF Margin % Related Terms

Statera BioPharma FCF Margin % Historical Data

* Premium members only.

The historical data trend for Statera BioPharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Statera BioPharma FCF Margin % Chart

Statera BioPharma Annual Data
Trend Dec19 Dec20 Dec21
FCF Margin %
0.00 0.00 0.00

Statera BioPharma Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:7CB vs NRBO, PALI, BLCM: FCF Margin % Comparison

For the Biotechnology subindustry, Statera BioPharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Statera BioPharma FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Statera BioPharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Statera BioPharma's FCF Margin % falls into.


Statera BioPharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Statera BioPharma's FCF Margin for the fiscal year that ended in Dec. 2021 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2021 )/Revenue (A: Dec. 2021 )
=-25.113/0
= %

Statera BioPharma's FCF Margin for the quarter that ended in Sep. 2022 is calculated as

FCF Margin=Free Cash Flow (Q: Sep. 2022 )/Revenue (Q: Sep. 2022 )
=-0.81/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Statera BioPharma (STU:7CB) has a FCF Margin % of 0.00% as of Sep. 2022. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Statera BioPharma and its competitors.
Is Statera BioPharma's FCF Margin % too high?
Statera BioPharma's current FCF Margin % is 0.00%. Overall, Statera BioPharma has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Statera BioPharma's FCF Margin % compare to NRBO and PALI?
Statera BioPharma's FCF Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Statera BioPharma and its competitors. Statera BioPharma's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Statera BioPharma stock overvalued right now?
Statera BioPharma (STU:7CB) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Statera BioPharma's overall GF Score™ is 20/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Statera BioPharma (STU:7CB), the current FCF Margin % is 0.00% as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Statera BioPharma Business Description

Address 2580 East Harmony Road, Suite 316, Fort Collins, CO, USA, 80528
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction. Its proprietary platform of Toll-like receptor drug candidates has applications in mitigation of radiation injury, mitigation of T-cell exhaustion, inflammation, T-cell exhaustion, immune system dysfunction, oncology, infection and neutropenia.